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Abstract
Background: Serum angiotensin-converting enzyme (ACE) 
activity determination can aid the early diagnosis of sar-
coidosis. We aimed to optimize a fluorescent kinetic assay 
for ACE activity by screening the confounding effects of 
endogenous ACE inhibitors and interfering factors. Gen-
otype-dependent and genotype-independent reference 
values of ACE activity were established, and their diagnos-
tic accuracies were validated in a clinical study.
Methods: Internally quenched fluorescent substrate, Abz-
FRK(Dnp)P-OH was used for ACE-activity measurements. 
A total of 201  healthy individuals and 59 presumably 
sarcoidotic patients were enrolled into this study. ACE 
activity and insertion/deletion (I/D) genotype of the ACE 
gene were determined.
Results: Here we report that serum samples should be 
diluted at least 35-fold to eliminate the endogenous 
inhibitor effect of albumin. No significant interfer-
ences were detected: up to a triglyceride concentration 
of 16 mM, a hemoglobin concentration of 0.71 g/L and a 
bilirubin concentration of 150 μM. Genotype-dependent 
reference intervals were considered as 3.76–11.25 U/L, 
5.22–11.59 U/L, 7.19–14.84 U/L for II, ID and DD genotypes, 
respectively. I/D genotype-independent reference interval 
was established as 4.85–13.79 U/L. An ACE activity value 
was considered positive for sarcoidosis when it exceeded 
the upper limit of the reference interval. The optimized 
assay with genotype-dependent reference ranges resulted 
in 42.5% sensitivity, 100% specificity, 100% positive pre-
dictive value and 32.4% negative predictive value in the 
clinical study, whereas the genotype-independent refer-
ence range proved to have inferior diagnostic efficiency.
Conclusions: An optimized fluorescent kinetic assay of 
serum ACE activity combined with ACE I/D genotype 
determination is an alternative to invasive biopsy for con-
firming the diagnosis of sarcoidosis in a significant per-
centage of patients.
Keywords: ACE; angiotensin-converting enzyme; 
 genotype; reference interval; sarcoidosis.
Introduction
Sarcoidosis is an idiopathic multisystem granulomatous 
disease that most commonly affects the lungs, lymph 
nodes and skin [1]. The diagnosis of sarcoidosis is estab-
lished when radiologic findings are supported by histo-
logic findings of noncaseating granulomas in the biopsy 
specimen and other causes of granulomas can be excluded 
[2]. There are no gold standard laboratory tests to facili-
tate earlier diagnosis, albeit several new biomarkers have 
been discovered in the last decades. Soluble interleukin-2 
receptor [3], chitotriosidase [4], serum amyloid A [5] and 
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other markers were tested as possible diagnostic marker, 
but only serum angiotensin-converting enzyme (ACE) 
seems to have diagnostic utility [6].
The metalloproteinase ACE catalyzes angiotensin 
II production, thus participating in the maintenance of 
blood pressure and the salt-water homeostasis [7]. ACE 
is a membrane protein expressed on the surface of many 
cells, released into the circulation by proteolytic cleavage 
[8]. Serum ACE originates primarily from the pulmonary 
microvasculature [9], and its concentration and activity are 
influenced by the insertion-deletion (I/D) polymorphism 
of the ACE gene [10]. Epitheloid cells of the sarcoid gran-
uloma produce ACE [11], which may reflect to the granu-
loma burden [12], and the granuloma is responsible for the 
higher serum ACE level in some sarcoidotic patients.
Beside genotype, endogenous ACE inhibition also sig-
nificantly influences the circulating ACE enzyme activity 
[13]. Serum albumin (reference range: 35–52 g/L) has been 
identified as an endogenous ACE inhibitor with an IC50 
between 5.7 and 9.5 g/L [14]. Majority of the commercially 
available ACE activity diagnostic tests propose using 1:5 
or 1:10 ratios of serum and substrate solution for meas-
urement. Endogenous inhibition of ACE by albumin is 
still present at those dilutions; consequently, ACE activity 
may be underestimated with these tests and sarcoidosis is 
underdiagnosed.
Here, we describe an optimized fluorescent kinetic 
assay for ACE activity measurement, in which the inhibi-
tory effect of albumin is eliminated and the interfering 
factors (hemolysis, icterus and lipemia) are determined. 
Genotype-independent and I/D polymorphism-depend-
ent reference intervals for ACE were established, and the 
accuracy of the optimized ACE activity assay was vali-
dated in a clinical study.
Materials and methods
Subjects
Two hundred and one Hungarian adults were enrolled to the con-
trol group from the outpatient clinic of the Department of Cardiol-
ogy, University of Debrecen, or from employees of the department. 
According to self-assessment, the majority was deemed to be healthy. 
Mild (type I) treated hypertension was not an exclusion criterion. 
None of them was treated with ACE inhibitor drugs, and all partici-
pants gave a written informed consent.
Fifty-nine patients were involved in a clinical study to evaluate 
the diagnostic accuracy of the optimized ACE activity assay in sar-
coidosis. These patients underwent a diagnostic mediastinoscopy or 
video-assisted thoracoscopic surgery in the Department of Surgery, 
University of Debrecen, for biopsy sampling intended to verify the 
lack or the presence of sarcoidosis by histopathology. Histopatho-
logic examinations were carried out routinely by the Department 
of Pathology, University of Debrecen. All patients gave their written 
informed consent.
Serum and DNA samples
Blood samples were obtained by standard aseptic technique into 
Vacutainer tubes (Cat. No. 368857, 367955, Becton Dickinson, Frank-
lin Lakes, NJ, USA). Sera were separated from native blood after clot-
ting and 15  min, 1500g centrifugation at +4 °C. Sera were stored at 
−20 °C until ACE activity measurement. The degree of hemolysis, 
icterus and lipemia was estimated with HIL indices measured on a 
Cobas C6000 analyzer (Roche, Basel, Switzerland), and sampling 
was repeated if the values exceeded 50, 50 and 200, respectively. In 
case of patients in clinical study, blood samples were taken immedi-
ately before surgery.
EDTA anticoagulated whole blood was taken for genetic deter-
minations and stored at −20 °C until deoxyribonucleic acid (DNA) 
isolation. The average time span between blood sampling and 
DNA isolation was 1  month (the range was 2  days to 3  months). 
Genomic DNA was prepared using NucleoSpin Blood kit (Cat. No: 
740951.50; Macherey-Nagel GmbH, Düren, Germany) according to the 
 manufacturer’s instruction, and purified DNA was stored at +4 °C.
ACE activity measurement with the fluorescent kinetic 
assay
Serum ACE activity was measured using the protocol of Carmona 
et  al. [15] with minor modification. Briefly, reaction mixture con-
tained in 100 mM tris(hydroxymethyl)aminomethane hydrochloride 
(TRIS) buffer (pH 7.0): 15 μM Abz-FRK(Dnp)P-OH substrate (synthe-
sized by Peptide 2.0, Chantilly, VA, USA), 50 mM NaCl, 10 μM ZnCl2 
and serum at 35-fold final dilution. Change in fluorescent intensity 
of reaction mixtures was measured by NovoStar plate reader (BMG 
Labtech GmbH, Ortenberg, Germany) in 96-well black plates (Cat. 
No: 655-900, Greiner Bio-One International GmbH, Kremsmünster, 
 Austria) at 37 °C. Continuous recording was done for 30  min with 
1-min measurement intervals, and the excitation and emission 
wavelengths were 340 and 405  nm, respectively. The activity was 
expressed in U/L and calculated by the following equation:
ACE activity / ,S k D= ∗
where S indicated the slope of the increase in fluorescence with time, 
k was the fluorescence intensity of 1 nM total hydrolysed substrate 
and D was the dilution of serum. ACE activity was measured at least 
twice for each sample to achieve a coefficient of variation of at most 
6%. ACE activity values reported as mean.
ACE activity measurement with the ‘ACEcolor  
diagnostic kit’
ACE activity of 40 out of 51 patients involved in the clinical study 
was measured with ACEcolor diagnostic reagent (Cat. No: 205259, 
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Fujirebio Inc, Tokyo, Japan) according to the manufacturers instruc-
tion. The applied serum dilution was the recommended sixfold, and 
the absorbance of reaction mixtures was measured by a Hitachi 
U-2900 spectrophotometer (Hitachi High-Technologies Corporation, 
Tokyo, Japan) at 505  nm in disposable cuvettes (Cat. No: 7591 15, 
Brand GmbH, Wertheim, Germany). The activity was expressed in 
IU/L and calculated by the suggested equation:
ACE activity ( ) 87.5,A B= − ∗
where A indicated the absorbance of sample mixture, and B indi-
cated the absorbance of sample blank mixture. Normal reference 
range (8.3–21.4 IU/L at 37 °C) under this test method was adopted 
from the kit booklet.
Interference testing
Hemolysis interference was examined using hemolysate, which 
was obtained from sodium-citrate anticoagulated whole blood of a 
healthy volunteer. Blood was washed with physiologic saline five 
times, and cell cytosol was liberated by freezing and thawing. Cell 
debris was removed by centrifugation at 16,000g, +4 °C, 15  min, 
and hemoglobin concentration was measured with sodium lauryl 
 sulfate-hemoglobin method in a Sysmex XE-2100  hematology ana-
lyzer (Kobe, Japan).
Intralipid (20%, Fresenius-Kabi, Bad Homburg, Germany) was 
added to normal sera to generate lipemic samples, then triglyceride 
concentration was measured using a glycerol-blanked triglyceride 
assay (Cat. No: 05975573 190, Roche, Basel, Switzerland) on a Cobas 
C6000 analyzer.
Unconjugated bilirubin (Cat. No: 14370, Merck Life Science, 
Darmstadt, Germany) was added to normal sera to simulate icteric 
samples, then total bilirubin concentration was measured using azo-
bilirubin method (Cat. No: 05168414 190 Roche, Basel, Switzerland) 
on a Cobas C6000 analyzer.
Significant interference was defined when the change of ACE 
activity exceeded 10% of the baseline value.
ACE genotyping
I/D genotype of ACE-gene was determined on the basis of the pro-
tocol described by Rigat et al. [16], and the presence of allele I was 
confirmed using a second polymerase chain reaction (PCR) with the 
method of Lindpaintner et al. [17]. Amplicons of these reactions were 
separated and evaluated using a single 3% agarose gel [10], and DNA 
was stained with SYBR safe gel stain (Cat. No: S33102, Thermo Fisher 
Scientific, Waltham, MA, USA).
Ethical approval
All studies were approved by the Regional and Institutional Ethics 
Committee, Clinical Centre, University of Debrecen, (UDCC REC/IEC 
number: 4375-2015) and by the Medical Research Council of Hungary 
(33327-1/2015/EKU). The research was in accordance the tenets of the 
Declaration of Helsinki.
Statistical analysis
χ2-Test was used to estimate if the genotype distribution in the con-
trol group was in Hardy-Weinberg equilibrium [18]. Gaussian dis-
tribution of ACE activity values was tested using Shapiro-Wilk test 
and D’Agostino-Pearson test. Reference intervals were defined as the 
middle 95% of the reference population (2.5th–97.5th percentiles). 
Differences in ACE activity among genotype-determined groups were 
tested by one-way ANOVA and Tukey’s multiple comparisons test. 
Differences in ACE activity values between samples with different 
concentration of triglyceride or hemoglobin or bilirubin were tested 
by unpaired t-test. Statistical analysis was performed using Graph-
Pad Prism software, version 7.00 (San Diego, CA, USA). Data are 
presented as mean ± standard deviation (SD) or median and range; 
p values <0.05 were considered statistically significant.
Results
Reversible endogenous inhibition of ACE by albumin can 
be eliminated by the appropriate dilution of serum. ACE 
activity of three serum samples obtained from healthy 
individuals with different ACE I/D genotypes was meas-
ured in serial dilutions (Figure 1). Calculated ACE activity 
values showed an exponential increase with the dilu-
tion in each genotype, reaching the maximum at 35-fold 
Figure 1: Inhibitory effect of albumin on ACE activity can be elimi-
nated by the 35-fold dilution of serum.
Calculated ACE activity values are plotted as a function of applied 
serum dilutions. Empty circles, triangles and squares represent data 
of three healthy individuals with genotype DD, ID and II, respec-
tively. Plots are fitted by means of one phase exponential decay, and 
symbols denote the means ± SD of two independent determinations. 
A 35-fold dilution is indicated by dashed red line. Please note, that 
somewhere the error bars are overlapped by the symbols.
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dilution. ACE activities measured at 35-fold dilution did 
not differ statistically from those values measured at 
70-fold dilution in all samples.
Next, hypothetical interferences of triglyceride, hemo-
globin and bilirubin on ACE activity were determined 
(Figure 2). Turbidity of sample did not affect the result of 
ACE activity reading. The ACE activity was constant for 
a triglyceride concentration up to 16 mM (Figure 2A). By 
contrast, hemolysis influenced significantly the results of 
the fluorescent kinetic assay at hemoglobin concentration 
of 0.35 g/L or higher (Figure 2B). A hemoglobin concentra-
tion of 0.71 g/L led to the underestimation of ACE activity 
by about 10%. Similarly, jaundice also affects measured 
ACE activities at total bilirubin concentration of 64 μM or 
higher (Figure 2C). Samples with bilirubin concentrations 
higher than 150 μM were associated with an apparent 10% 
decrease of ACE activity.
Data of 201 individuals were involved in the determi-
nation of genotype-dependent and genotype-independ-
ent ACE activity reference values. ACE I/D genotype and 
ACE activity at 35-fold dilution were determined and basic 
clinical data of subjects were collected (Table 1). Genotype 
distribution of the whole population was in Hardy-Wein-
berg equilibrium (χ2 = 1.276 with two degrees of freedom, 
p = 0.5283). ACE activity values showed normal distribu-
tion using Shapiro-Wilk test (II: 7.30 ± 1.65 U/L, p = 0.97, 
n = 39; ID: 8.72 ± 1.70 U/L, p = 0.30, n = 90, DD: 10.6 ± 1.70 
U/L, p = 0.41, n = 72; all subjects: 9.12 ± 2.08 U/L, p = 0.64, 
n = 201) and D’Agostino-Pearson test (II: p = 0.94; ID: 
p = 0.09, DD: p = 0.26; all subjects: p = 0.49). The ACE I/D 
genotype significantly influenced ACE activity, as indi-
viduals with II genotype showed lower ACE activity than 
individuals with DD genotype, while subjects with ID 
geno type showed a mid-range activity (II: 7.30 ± 1.65 U/L; 
Figure 2: Hemolysis and icterus decrease the ACE activity.
ACE activity values, expressed as % of maximum, are plotted as a function of triglyceride (mM, A), hemoglobin (g/L, B) or bilirubin (μM, C) 
concentration. Symbols denote the means ± SD of three independent determinations. Significant differences (unpaired t-test) from samples 
with the lowest triglyceride or hemoglobin or bilirubin concentration are indicated by asterisk (*). More than 10% decrease in ACE activity 
compared to baseline is indicated by red cycles.
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ID: 8.72 ± 1.70 U/L; DD: 10.6 ± 1.70 U/L, p < 0.0001) 
(Figure  3A). Normal reference intervals for each group 
were calculated and summarized on Figure 3B.
Diagnostic accuracy of this ACE activity assay was 
tested in a clinical trial. Fifty-nine patients were enrolled in 
the study, who all underwent diagnostic mediastinoscopy 
Table 1: Characteristics of control group.
Female Male Total
Number, n 110 91 201
Age, years (mean ± SD) 54.71 ± 14.90 54.85 ± 14.16 54.78 ± 14.52
BMI, kg/m2 27.29 ± 5.83 29.13 ± 5.03 28.13 ± 5.54
Smoker, n 12 15 27
Systolic blood pressure, mmHg (mean ± SD) 128.35 ± 18.68 128.75 ± 15.48 128.5 ± 17.22
Diastolic blood pressure, mmHg (mean ± SD) 78.42 ± 10.24 80.90 ± 9.90 79.56 ± 10.13
Left ventricular EF, % (mean ± SD) 59.07 ± 6.49 56.20 ± 6.78 57.71 ± 6.76
ACE-activity, U/L (mean ± SD) 9.10 ± 2.06 9.15 ± 2.10 9.12 ± 2.07
II genotype, n 18 21 39
ID genotype, n 44 46 90
DD genotype, n 48 24 72
BMI, body mass index; EF, ejection fraction; ACE, angiotensin-converting enzyme.
Figure 3: ACE I/D genotype influences the serum ACE activity.
Serum ACE activity distribution (A) and normal reference ranges 
(B) are shown according to ACE I/D genotype (insertion, II, n = 39; 
heterozygotes, ID, n = 90; deletion, DD, n = 72; all individuals, 
n = 201). The boxes indicate the interquartile range with median; 
whiskers are the 2.5th and 97.5th percentiles. Outliers are plotted 
as individual points (empty cycles). Significant differences (one-way 
ANOVA, Tukey’s multiple comparisons test) among genotype groups 
are labeled by asterisks (*).
or thoracoscopy for hilar lymph node or lung tissue 
biopsy motivated by the symptoms of sarcoidosis. Diag-
nosis of sarcoidosis was established or ruled out by histo-
pathologic examination of these biopsy specimen. Blood 
samples were taken from each patient before surgery for 
genotyping and ACE activity measurement. Patients under 
steroid therapy were excluded from the study. Eight out 
of 59 patients were excluded from the evaluation because 
they took ACE inhibitors and had an artificially low serum 
ACE activity. Histopathologic examination was specific for 
sarcoidosis in 40 out of 51 patients, and 11 patients had 
histologically different diagnoses (lymphoma, carcinoma, 
anthracosis, sinus histiocytosis, etc.). Concerning the 
prevalence of ID genotype and allele frequencies, there 
were no statistically significant differences between histo-
logically positive and negative groups for sarcoidosis, and 
between positive for sarcoidosis and control group (data 
not shown). Clinical characteristics of patients are listed 
in Table 2.
An ACE activity value was considered positive for sar-
coidosis, when it exceeded the upper limit of the reference 
interval. Nine out of 40 sarcoidotic patients had ACE activ-
ity higher than the upper limit of the reference range when 
genotype-independent reference interval was applied, and 
17 out of 40 sarcoidotic patients had ACE activity higher 
than the upper limit of reference range when genotype-
dependent reference interval was used (Table 3). Thereby, 
the sensitivity of ACE activity determination for confirm-
ing the diagnosis of sarcoidosis is greatly improved by 
genotype-dependent reference intervals (42.5% vs. 22.5%). 
Eleven out of the 51 patients had true negative results 
which finally proved to be negative based on both evalu-
ation techniques, and 31 and 23 patients were false nega-
tive with genotype-independent and genotype-dependent 
reference intervals, respectively. Specificity and positive 
predictive value (PPV) were 100% in both cases, whereas 
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Table 2: Characteristics of patients enrolled in the clinical study.
Total number of patients, n   59
Excluded patients because of ACE 
inhibitor treatment, n
  8
  Positive histology 
for sarcoidosis
  Negative histology 
for sarcoidosis
Number, n   40   11
Age, year (mean ± SD)   39.0 ± 11.0   54.0 ± 15.2
Gender, n (female/male)   18/22   3/8
II genotype, n   4   3
ID genotype, n   24   5
DD genotype, n   12   3
ACE activity (II), U/L (mean ± SD)   10.38 ± 3.67   5.73 ± 0.91
ACE activity (ID), U/L (mean ± SD)   12.24 ± 4.35   7.38 ± 2.90
ACE activity (DD), U/L (mean ± SD)   13.99 ± 4.82   10.97 ± 0.70
Radiographic stage of lung disease
 Stage 0, n   1   0
 Stage I, n   24   8
 Stage II, n   11   3
 Stage III, n   3   0
 Stage IV, n   0   0
Left ventricular EF, % (mean ± SD)   60.4 ± 4.8   61.1 ± 5.4
FVC, % (mean ± SD)   96.0 ± 16.5   85.8 ± 19.1
FEV1, % (mean ± SD)   92.7 ± 15.0   80.0 ± 18.8
Tiffeneau-index, % (mean ± SD)   82.82 ± 5.82   79.05 ± 7.13
ACE, angiotensin-converting enzyme; EF, ejection fraction; FVC, forced vital capacity; FEV1, forced expiratory volume (1 s); Tiffeneau-index, 
FEV1/FVC.
Table 3: Diagnostic accuracy of fluorescent kinetic ACE activity 
assay.
  Evaluation with 
genotype-independent 
decision limit
  Evaluation with 
genotype-dependent 
decision limits
True positive, n   9   17
True negative, n   11   11
False positive, n   0   0
False negative, n   31   23
Sensitivity, %   22.5   42.5
Specificity, %   100.0   100.0
PPV, %   100.0   100.0
NPV, %   26.2   32.4
Accuracy, %   39.2   54.9
PPV, positive predictive value; NPV, negative predictive value.
Table 4: Diagnostic accuracy of ACEcolor diagnostic assay and the 



















True positive, n   6   6   9
True negative, n   10   11   11
False positive, n   1   0   0
False negative, n  23   23   20
Sensitivity, %   20.7   20.7   31.3
Specificity, %   90.9   100   100
PPV, %   85.7   100   100
NPV, %   30.3   32.4   35.5
Accuracy, %   40   42.5   50
PPV, positive predictive value; NPV, negative predictive value.
negative predictive value was 26.2% and 32.4% according 
to genotype-independent and genotype-dependent refer-
ence ranges, respectively. The accuracy of the ACE activity 
assay was higher when the genotype-dependent reference 
interval was applied (54.9% vs. 39.2%).
We compared the diagnostic accuracy of this fluo-
rescent kinetic assay to a commercial available diag-
nostic test, ‘ACEcolor’ (Table 4). Based on 40 out of 51 
patient’s ACE activity values, the diagnostic accuracy 
of our test (with genotype-independent decision limit) 
was similar to the accuracy of ‘ACEcolor’ test (42.5% 
vs. 40%, respectively), although ‘ACEcolor’ identified 
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a non-sarcoidotic sample as false positive. When geno-
type-dependent decision limits were used, our test was 
superior to ‘ACEcolor’ diagnostic test (50% vs. 40%, 
respectively).
Discussion
Measurement of ACE activity from human serum can 
provide physicians with essential information for diag-
nosing some diseases, such as sarcoidosis [19], Gaucher 
disease [20] and granulomatous infections [21]. ACE activ-
ity seems to be a useful biomarker for the diagnosis and 
monitoring of sarcoidosis [6]. Radiolabeled, colorimetric 
and fluorometric assays are available to measure serum 
ACE activity, and recently a rapid, very sensitive fluores-
cent kinetic assay has been developed using an internally 
quenched fluorogenic substrate (Abz-FRK(Dnp)P-OH) [22]. 
Here we further optimized this test to eliminate inhibitory 
effects of the endogenous ACE inhibitor albumin. Inter-
fering factors were revealed and normal reference ranges 
were determined for this method.
Albumin-mediated endogenous ACE inhibition 
is reversible, which means that the degree of inhibi-
tion is highly affected by the degree of dilution during 
measurement. In other words, inhibition can be elimi-
nated by appropriate dilution of the sample. We iden-
tified, that albumin-mediated inhibition on serum ACE 
becomes negligible at 35-fold or higher dilution of sera. 
The 35-fold serum dilution is applicable in case of all the 
three ACE I/D genotypes; therefore, it is not necessary to 
know the patient’s I/D genotype for the measurement, 
only for the evaluation of results. It is important to note 
that the 35-fold dilution is not sufficient to eliminate the 
exogenous interfering effects of ACE inhibitor drugs. 
Before the ACE activity measurement, patients treated 
with ACE inhibitors are recommended to be switched 
to another type of drug, such as angiotensin II receptor 
blocker.
Manufacturers of ACE activity diagnostic reagents 
suggest a 5- or 10-fold final dilution of serum despite the 
fact that Lieberman and Sastre [23] have already called 
attention to the importance of serum dilution in 1986. 
These authors examined 6-, 12-, 24- and 48-fold final dilu-
tions, and they suggested 48-fold final dilution (8-fold 
before assay and 6-fold during measurement) to eliminate 
the effects of endogenous inhibitors. This is in accordance 
with our findings because we have found that ACE is par-
tially inhibited at a 24-fold dilution, but apparently unin-
hibited at 35-fold dilution.
Endogenous interference studies have revealed that 
icterus and hemolysis may interfere with this fluorescent 
kinetic activity assay. Considering the slight individual 
variability of serum ACE activity and the fact that in some 
sarcoidotic patients ACE activity increases only to a small 
extent, we suggest 10% decrease in ACE activity due to inter-
ference to be considered as significant. Previously, it was 
reported that bilirubin decreases the apparent ACE activity 
in spectrophotometric but not in radionuclide assays [24]. 
Bilirubin can directly bind to ACE and modulate its confor-
mation, thereby influencing ACE shedding from endothelial 
cells [25] and maybe ACE activity as well. A large amount of 
hemoglobin is released from red blood cells during hemoly-
sis. Hemoglobin shows strong absorbance at 415-, 540- and 
570-nm wavelengths [26]. This assay measures change in 
fluorescent intensity at 405  nm. In hemolysed samples, 
the emitted light can partially be absorbed by cell free 
hemoglobin, which may result in decreased apparent ACE 
activity readings. On the other hand, it cannot be excluded 
that hemoglobin exerts some kind of direct effects on ACE. 
Lipemia does not influence the assay for a triglyceride con-
centration of 16  mM; thus, fasting blood sampling is not 
crucial. Relying upon these findings, further dilution of 
serum samples with hemoglobin concentration of >0.71 g/L 
or bilirubin concentration of >150 μM is required to elimi-
nate probable effects of interfering factors.
We determined genotype-dependent and genotype-
independent ACE activity reference values relying on the 
data of 201 Hungarian individuals. To our knowledge, 
this is the first time that reference ranges has been pub-
lished using this ACE activity assay. Current guidelines 
of Clinical and Laboratory Standards Institute [27] and 
European Federation of Clinical Chemistry and Labora-
tory Medicine [28] recommend the involvement of at least 
120 individuals into a reference group. Although our 
 genotype-independent reference group (n = 201) fulfils 
this recommendation, the numbers of individuals are less 
than 120 in each genotype-dependent reference group, 
representing a limitation of these reference intervals. 
The I/D genotype distribution in our reference popula-
tion (II = 19.4%; ID = 44.8%; DD = 72%) was in accordance 
with the previously published data in Caucasians [29–31], 
and the mean ACE activity values were also statistically 
different (p < 0.0001) among these genotype groups. Our 
genotype-dependent reference ranges overlap with each 
other from the value of 7.19 U/L (the lower reference limit 
of group DD) to the value of 11.25 U/L (the upper refer-
ence limit of group II). We suggest that ACE I/D geno-
type should only be determined when the measured ACE 
activity value is higher than 11.25 U/L. Patients with ACE 
activity higher than 11.25 U/L will especially benefit from 
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genotyping and applying the genotype-dependent refer-
ence intervals. This method may help rationalizing the 
expenses of genotyping.
It is important to note that this assay results in much 
lower ACE activity values than other methods [32, 33]. The 
data presented here confirm that the internally quenched 
fluorogenic substrate (Abz-FRK(Dnp)P-OH has a slower 
hydrolysis rate than that for other substrates, such as used 
in the ‘ACEcolor’ assay (Table 4). However, the fluorogenic 
detection of the decomposition of the (Abz-FRK(Dnp)P-OH 
is more sensitive, making this substrate preferred in this 
report. It needs also be highlighted that here we showed 
that ACE is endogenously inhibited by a common ingre-
dient of the samples, namely by albumin. Hence, earlier 
data are biased by the unknown contribution of albumin 
inhibition to the measured ACE activities. Here we used an 
inferior substrate (lower conversion rate) to set up a more 
sensitive assay and provided a method to eliminate the 
albumin mediated inhibitory effect.
Diagnostic accuracy of this fluorescent kinetic assay 
was tested in a clinical study. Sarcoidosis suspect patients 
underwent diagnostic surgery to collect tissue samples for 
histopathology, and at the same time ACE activity was also 
determined from serum samples. Patients with ACE activ-
ity values exceeding the upper limit of the reference inter-
val were considered positive for sarcoidosis. Almost twice 
as much patients proved to be positive for sarcoidosis 
according to the genotype-dependent reference intervals 
compared to those evaluated according to the genotype-
independent reference range. Applying this ACE activity 
assay and genotype-dependent reference intervals, the 
diagnosis of sarcoidosis can be confirmed with 42.5% 
sensitivity, 100% specificity and 100% PPVs. This ACE 
activity assay and the applied reference ranges did not 
result in any false positive cases; therefore, the number 
of false negative cases became higher and the sensitivity 
lower. With other words, the false-positive results were 
eliminated by sacrificing the sensitivity. Consequently, 
the presence of symptoms consistent with the diagnosis of 
sarcoidosis and ACE activity values exceeding the upper 
limit of the reference range should prompt physicians to 
consider initiation of pharmacological treatment instead 
of performing surgical biopsy.
Various methods and diagnostic kits can be used to 
measure ACE activity. Comparison of diagnostic accuracy 
of the fluorescent kinetic assay presented here to another 
commercial ACE activity kit revealed a slight superiority 
of the fluorescent kinetic assay. On the other hand, iden-
tification of the ACE I/D genotype significantly improved 
both sensitivity and specificity to detect sarcoidosis irre-
spectively of the method used to measure the activity.
In conclusion, we have further optimized a fluores-
cent kinetic ACE activity method, when the assay is not 
interfered with endogenous ACE inhibitor albumin. Using 
our genotype-dependent reference intervals and cutoff 
values, this test might be an alternative to invasive biopsy 
for confirming the diagnosis of sarcoidosis in almost half 
of patients.
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